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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 















• A large study in the US 
explored long term 
(~6months) clinical 
outcomes for patients 
with COVID-19 which 
may support global 
discussion on the post-
acute manifestations of 
COVID-19, and further 
support health system 
planning and strategies. 
• The study analyses data 
from the Veteran Health 
Administration including 
data from 73 435 people 
with COVID-19 who 
survived at least 30 
days after diagnosis and 
were not hospitalised 
and 4,990, 835 people 
without COVID-19 and 
were not hospitalised. 
Analysis showed that 
people with COVID-19 
who survived at least 30 
days after illness had an 










• A high dimensional 
approach identified 
sequalae including : 
respiratory conditions, 
diseases of the nervous 
system, mental health, 
metabolic 





pain and anaemia, 
indicating increased 
health care utilisation 
and greater burden of ill 
health. 
• A comparative 
evaluation in a cohort of 
hospitalised patients 
with COVID-19 (13 654) 
and those hospitalised 
with seasonal flu (13 
997) was also 
conducted.  
o People with 
COVID-19 who 
survived at least 
30 days after 
illness  had 










higher risk of 
outpatient care 
encounter.  
o In comparison to 




• The authors discuss that 
the mechanisms for 
post-acute and chronic 
manifestations are 
unclear and may be a 
driven by direct and 
indirect mechanisms. 




report of a 




• WHO in collaboration 
with others hosted a 
webinar entitled 
‘Expanding our 
understanding of Post 
COVID-19 condition’. 
This webinar was 
attended by over 700 
participants. The 
webinar was divided into 
three sessions: 1. Post 
COVID-19 condition: 
scene setting and 
lessons learnt; 2. 
Observations on Post-
Covid-19 condition: what 
we know; and Working 
groups to develop 
clinical definition and 
research gaps.   
• Post COVID-19 
condition: scene setting 
and lessons learnt: this 
included a serious of 
presentations on 1. 
Learning from past 
pandemics 2. Learnings 
from global forums 3. 
Exploring mechanisms 
4. WHO update on Post-
covid codes, clinical 
management guidelines 









• Observations on Post-
Covid-19 condition show 
cased findings from 
research including a 
multi-country cohort (56 
countries), and cohort 
studies in China, Italy, 
Brazil and India. 
• Working groups 
identified that there has 
been a lack of 
harmonisation across 
the studies; a need to 
characterise and define 
Post-COVID-19, and 
then develop 
diagnostics to support; 
they also identified 
research gaps, such as 
drug trials for symptom 
management, and a 
need to understand the 
pathophysiology that 
lead to Post-Covid-19 
conditions. Outcomes 
from the working groups 
are now being used to 
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A systematic review and meta-
analysis was conducted to 
explore corticosteroid therapy 
in patients with COVID-19. 52 
trials were included (15710 
participants). These included 
18 multicentre trials and 35 
single-centre trials. 
• The meta-analysis 
showed that less 
patients received 
corticosteroids 
(35.19%) than did not 
(64.49%). There was 







in the proportion of 
severe and non-
severe cases treated 
with corticosteroids. 
• 5 trials compared viral 
clearance. The pooled 
estimates showed that 
corticosteroid 
treatment significantly 
delayed the viral 
clearance time, 
however the authors 
note that there was 
significant 
heterogeneity 
amongst the studies. 
• 15 trials explored 
effect on mortality. 
The authors report 
that the meta-analysis 
demonstrated no 
significant difference 
for patients who 
received 
corticosteroids and 
died or survived. 




• The authors conclude 
therefore  that ‘ 
corticosteroids should 
be used with extreme 





controlled clinical trials 
are needed to verify 
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• Vaccine dosing protocols 
for  two vaccines which 
require 2 doses are 
modelled. The research 
involved modelling 
different vaccine strategies 
in the US. 
• Results indicate that a 
delay of a least 9 weeks 
for  Moderna vaccines, 
could maximize 
vaccination program 
effectiveness and avert at 
least an additional 17.3 
infections, 
0.69  hospitalizations, and 
0.34  deaths per 10,000 
population compared to 
the recommended 4-week 
interval between the 2 
doses.  
• Delaying to 9 weeks for 
second dose for Pfizer-
BioNTech vaccines 
averted an additional 
0.60  hospitalizations and 
0.32 deaths per 10,000 
population compared to 
the 3-week recommended 
schedule between doses. 
However, the authors 
summaries that ‘there was 
no clear advantage of 
delaying the second dose 
with Pfizer-BioNTech 
vaccines in reducing 
infections, unless the 
efficacy of the first dose 












• People with disabilities are 
disproportionately affected 
by COVID-19. This report 
was developed through a 
rapid scoping review of the 










amongst WHO and 
UNICEF with feedback 
from NGOs. 
• People with disabilities are 
a diverse group, and 
therefore the risks, 
barriers and impacts with 
vary by context, age, 
gender, ethnicity, sexual 
orientation, migration 
status and type of 
disability. 
• People with disabilities are 
at greater risk of 
contracting COVID-19 due 
to barriers implementing 





challenges. They may be 
at greater risk of severe 
disease/death due to 
underlying health 
conditions and barriers to 
accessing care. 
• The report outline actions 
for Persons with 





Organizations of persons 
with disabilities, Disability 
service providers, 
Residential institutions and 


















• ‘Access to COVID-19 
Tools (ACT) Accelerator 
was founded on a belief 
in global collaboration 
and solidarity and a 
shared commitment to 
ensure all people get 
access to the tools 
needed to defeat 
COVID-19’. It was 
launched in April 2020. 
This report outlines key 
achievements since this 
time and current 
priorities, including 
diagnostics, therapeutics 
and vaccines. This 
reports calls for  more 
funding to address global 
inequities in all three 
pillars. ACT identifies a 
funding gap of US$19 
billion. 
• Dr Tedros Adhanom 
Ghebreyesus highlights 
‘The inequitable 
distribution of tools is not 
just a moral outrage, it is 
also economically and 
epidemiologically self-
defeating. The more 
transmission, the more 
variants. And the more 
variants that emerge, the 
more likely it is that they 
could evade diagnostics, 
vaccines and even 
therapeutics. And as long 
as the virus is circulating 
anywhere, the longer the 
global recovery will take.’ 
• Diagnosis: The report 
highlights that in 2020 
less than 1 in 5 health 
facilities across Africa 
had access to tests. 
Less invasive/self tests 







isolate’,   
plans include ramping up 
genomic sequencing 
capacity and monitoring. 
• Therapeutics: Many 
clinical trials are ongoing 
analysing effectiveness 
of therapeutics. 
• Vaccines: COVAX is 
aiming to supply at least 
2 billion vaccines. The 
task force is also working 
to support 
manufacturing. African 
leaders are working to 
establish 5 vaccine 
manufacturing hubs over 
















• Due to lockdowns and 
associated measures, 
access and provision 
of healthcare which is 




diseases, sexual and 
reproductive health, 
new-born and child 
health and gender-
based violence.  
• Baseline vulnerabilities 
such as lack of safe 
housing, water and 
health care further 
perpetuate these 
impacts. This is 
particularly significant 
for LMICs and social 
groups such as 
women, children, 
elderly, people with 
disabilities, migrant 
workers, ethnic and 
religious minorities, 








people living in 
conflict-affected areas. 
• An equitable and 
socially justice 









and monitoring and 
implementation. Short 
term action should 





coverage and address 
social determinants. 
• This analysis was 
conducted as a rapid 
evidence assessment 
by the Social Science 
and Humanitarian 
Action Platform. 
• The authors conclude 
‘this paper calls for 
more holistic 
approaches to health 
in the context of 
COVID-19, but also 
beyond it, and urge 
action to mitigate 
tragedy in both the 




Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
May 2021 COVID-19 vaccines: building and maintaining 
confidence 
The Lancet Haematology| 
Editorial 
24.04.2021 Statelessness in the COVID-19 pandemic The Lancet| World Report 
24.04.2021 Global health and its discontents The Lancet| 
Correspondence 
23.04.2021 COVID-19 continues to disrupt essential health 
services in 90% of countries 
WHO| News 
23.04.2021 Covid-19: Infections fell by 65% after first dose of 
AstraZeneca or Pfizer vaccine, data show 
The BMJ| News 
22.04.2021 Covid-19: India looks to import oxygen as cases 
surge, overwhelming hospitals 
The BMJ| News 
22.04.2021 A conceptual framework to accelerate the clinical 
impact of evolving research into long COVID 
The Lancet Infectious 
Diseases| Comment 
21.04.2021 Covid-19 new variants—known unknowns The BMJ| Opinion 
21.04.2021 Covid-19: Unusual blood clots are “very rare side 
effect” of Janssen vaccine, says EMA 
The BMJ| News 
20.04.2021 Covid-19: Spike in cases in Chile is blamed on 
people mixing after first vaccine shot 
The BMJ| News 
20.04.2021 COVID-19: The therapeutic landscape Med| Commentary 
19.04.2021 Leave no one behind: ensuring access to COVID-
19 vaccines for refugee and displaced populations 
Nature| Comment 
19.04.2021 Saliva as a gold-standard sample for SARS-CoV-
2 detection 
The Lancet Respiratory 
Medicine| Comment 
19.04.2021 Statement on the seventh meeting of the 
International Health Regulations (2005) 
Emergency Committee regarding the coronavirus 
disease (COVID-19) pandemic 
WHO| News 
   
 
Dashboards & Trackers     












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs    







Health Topics   Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 







  IDA 











































































Institute of Public 
Health 
    





Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 




  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  












      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
13.05.2021 Covid and mental health Webinar 2h 15 BMJ 
15.04.2021 How can evaluation 
work support greater 
vaccine equity for 
COVID-19? 
Webinar 1h Itad 
12.04.2021 COVID-19: Vaccines 
Safety Webinar - 
Understanding the Facts 
& Myths 
Webinar 1.5h Asia Pacific 
Association of 
Allergy, Asthma and 
Clinical Immunology 
07.04.2021 Public webinar 'The 
RECOVERY Trial: one 
year on' 
Webinar 1h Nuffield Department 
of Population Health 
25 March 
2021 
UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
Online courses Varies WHO 
emergencies, now offers 
10 online courses 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 











COVID-19 Open online 
brief with Dr David 
Nabarro 





Online learning 3 hours WHO 
COVID-19: methods for 
detection, prevention, 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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